Bristol-Myers' Hepatitis C combo gets breakthrough designation

The FDA has granted breakthrough designation to Bristol-Myers Squibs' (BMY) Daclatasvir and Asunaprevir combination oral treatment for Hepatitis C.

Specifically, the designation applies to the treatment of genotype 1b chronic hepatitis C and is based on the results of an ongoing Phase III trial.

The FDA's decision comes after European regulators said they would give an accelerated review to Daclatasvir when used in combination with other drugs. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs